PDF herunterladen
Horm Metab Res 1997; 29(3): 135-137
DOI: 10.1055/s-2007-979006
Minisymposium

© Georg Thieme Verlag Stuttgart · New York

Unresolved Issues in the Genesis and Management of Multiple Endocrine Neoplasia Type 2

R. F. Gagel
  • Section of Endocrinology, University of Texas M.D. Anderson Cancer Center, Houston, Texas, U.S.A.
Weitere Informationen

Publikationsverlauf

1996

1997

Publikationsdatum:
23. April 2007 (online)

Auch verfügbar auf
  als PDF herunterladen  Lizenzen und Reprints

It has been slightly less than 3 years since mutations of the RET proto-oncogene were identified in multiple endocrine neoplasia type 2. The period since the initial report has been one of intense activity with a wide spectrum of mutations identified in exons 10, 11, 13, 14, 15 and 16 of this gene. Recent studies have provided experimental evidence for an activating effect of the exon 11 and 16 mutations. Two questions are addressed in this report: the high rate of false positive tests in prospective screening studies and the implications for future interpretation of this test: and the mechanism of transformation in MEN 2.

Key words

RET Proto-Oncogene - Medullary Thyroid Carcinoma - Multiple Endocrine Neoplasia Pentogastrin